Globus Medical (NYSE:GMED) Issues FY 2026 Earnings Guidance

Globus Medical (NYSE:GMED) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 4.950-5.050 for the period, compared to the consensus EPS estimate of 5.000. The company issued revenue guidance of $3.1 billion, compared to the consensus revenue estimate of $3.2 billion.

Analyst Upgrades and Downgrades

GMED has been the subject of several analyst reports. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Globus Medical in a research note on Friday, October 9th. Truist Financial cut their price target on shares of Globus Medical from $115.00 to $100.00 and set a “buy” rating on the stock in a report on Thursday, July 16th. Royal Bank Of Canada reduced their price objective on shares of Globus Medical from $115.00 to $85.00 and set an “outperform” rating on the stock in a research note on Thursday, October 1st. Stifel Nicolaus cut their target price on Globus Medical from $95.00 to $80.00 and set a “hold” rating on the stock in a report on Wednesday, July 8th. Finally, BTIG Research reiterated a “neutral” rating on shares of Globus Medical in a research report on Friday, September 18th. Three investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Globus Medical presently has an average rating of “Moderate Buy” and a consensus target price of $99.46.

Globus Medical Stock Performance

Shares of NYSE:GMED traded down $5.97 during trading on Thursday, reaching $81.13. The stock had a trading volume of 3,034,249 shares, compared to its average volume of 1,474,554. Globus Medical has a 52 week low of $60.36 and a 52 week high of $101.40. The firm’s fifty day moving average is $77.48 and its 200 day moving average is $83.35. The stock has a market cap of $10.89 billion, a price-to-earnings ratio of 20.75, a P/E/G ratio of 1.28 and a beta of 0.98.

Globus Medical (NYSE:GMED) last announced its earnings results on Thursday, August 6th. The medical device company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.10 by $0.24. The business had revenue of $789.61 million during the quarter, compared to the consensus estimate of $782.88 million. Globus Medical had a net margin of 17.02% and a return on equity of 14.57%. Globus Medical’s quarterly revenue was up 5.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.86 earnings per share. On average, research analysts forecast that Globus Medical will post 4.99 earnings per share for the current fiscal year.

Insider Transactions at Globus Medical

In other Globus Medical news, Director Stephen Zarrilli sold 25,000 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the completion of the sale, the director directly owned 25,000 shares in the company, valued at approximately $2,176,000. This trade represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director James R. Tobin sold 30,000 shares of Globus Medical stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $74.58, for a total value of $2,237,400.00. Following the completion of the transaction, the director directly owned 15,000 shares of the company’s stock, valued at approximately $1,118,700. This trade represents a 66.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 18.38% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.